Warren H Tseng1, Steve R Martinez. 1. Department of Surgery, Division of Surgical Oncology, University of California Davis, Sacramento, California, USA.
Abstract
BACKGROUND: Prior studies documented poorer outcomes in patients with cutaneous head and neck melanoma (CHNM) relative to those with melanoma at other sites. We evaluated survival differences attributable to tumor location in patients with CHNM. METHODS: We queried the Surveillance, Epidemiology, and End Results (SEER) database for patients undergoing surgery for CHNM from 1988 to 2006, excluding patients without biopsy-proven diagnoses, those diagnosed at autopsy, and patients with distant metastases. Using the Kaplan-Meier method, we assessed patient, tumor, and treatment-specific factors on overall survival (OS) and melanoma specific survival (MSS). Cox proportional hazards models assessed the role of tumor location (ear, eyelid, face, lip, scalp/neck) on OS and MSS, while controlling for patient age, gender, race, tumor thickness, tumor ulceration, lymph node status, histologic subtype, type of surgery, and use of radiation. Risks of overall and melanoma-specific mortality were reported as hazard ratios (HR) with 95% confidence intervals (CI). RESULTS: Among 27,097 patients, 10-y rates of OS and MSS were 56.1% and 84.7%, respectively. On multivariate analysis, scalp/neck primary site was associated with an increased risk of overall (HR 1.20, CI 1.14-1.26; P < 0.001) and melanoma-specific mortality (HR 1.64, CI 1.49-1.80, P < 0.001) relative to melanomas of the face. Tumors of the lip had poorer MSS (HR 1.55; CI 1.05-2.28, P = 0.03) but not OS (HR 1.03, CI 0.80-1.34; P = 0.80). CONCLUSIONS: Patients with melanomas of the scalp/neck have poorer OS and MSS and those with lip melanomas have poorer MSS. These anatomic areas should not be overlooked when performing skin examinations.
BACKGROUND: Prior studies documented poorer outcomes in patients with cutaneous head and neck melanoma (CHNM) relative to those with melanoma at other sites. We evaluated survival differences attributable to tumor location in patients with CHNM. METHODS: We queried the Surveillance, Epidemiology, and End Results (SEER) database for patients undergoing surgery for CHNM from 1988 to 2006, excluding patients without biopsy-proven diagnoses, those diagnosed at autopsy, and patients with distant metastases. Using the Kaplan-Meier method, we assessed patient, tumor, and treatment-specific factors on overall survival (OS) and melanoma specific survival (MSS). Cox proportional hazards models assessed the role of tumor location (ear, eyelid, face, lip, scalp/neck) on OS and MSS, while controlling for patient age, gender, race, tumor thickness, tumor ulceration, lymph node status, histologic subtype, type of surgery, and use of radiation. Risks of overall and melanoma-specific mortality were reported as hazard ratios (HR) with 95% confidence intervals (CI). RESULTS: Among 27,097 patients, 10-y rates of OS and MSS were 56.1% and 84.7%, respectively. On multivariate analysis, scalp/neck primary site was associated with an increased risk of overall (HR 1.20, CI 1.14-1.26; P < 0.001) and melanoma-specific mortality (HR 1.64, CI 1.49-1.80, P < 0.001) relative to melanomas of the face. Tumors of the lip had poorer MSS (HR 1.55; CI 1.05-2.28, P = 0.03) but not OS (HR 1.03, CI 0.80-1.34; P = 0.80). CONCLUSIONS:Patients with melanomas of the scalp/neck have poorer OS and MSS and those with lip melanomas have poorer MSS. These anatomic areas should not be overlooked when performing skin examinations.
Authors: L Jansen; H S Koops; O E Nieweg; M H Doting; B A Kapteijn; A J Balm; A Vermey; J T Plukker; C A Hoefnagel; D A Piers; B B Kroon Journal: Head Neck Date: 2000-01 Impact factor: 3.147
Authors: I Pathak; C J O'Brien; K Petersen-Schaeffer; E B McNeil; J McMahon; M J Quinn; J F Thompson; W H McCarthy Journal: Head Neck Date: 2001-09 Impact factor: 3.147
Authors: C M Balch; S J Soong; G W Milton; H M Shaw; V J McGovern; T M Murad; W H McCarthy; W A Maddox Journal: Ann Surg Date: 1982-12 Impact factor: 12.969
Authors: M M Urist; C M Balch; S J Soong; G W Milton; H M Shaw; V J McGovern; T M Murad; W H McCarthy; W A Maddox Journal: Ann Surg Date: 1984-12 Impact factor: 12.969
Authors: Shannon H Beal; Steve R Martinez; Robert J Canter; Steven L Chen; Vijay P Khatri; Richard J Bold Journal: Med Oncol Date: 2010-01-05 Impact factor: 3.064
Authors: Nancy E Thomas; Klaus J Busam; Lynn From; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Alison Venn; Peter A Kanetsky; Pamela A Groben; Honglin Hao; Irene Orlow; Anne S Reiner; Li Luo; Susan Paine; David W Ollila; Homer Wilcox; Colin B Begg; Marianne Berwick Journal: J Clin Oncol Date: 2013-10-14 Impact factor: 44.544
Authors: T Harshani Peiris; Daniel Ramirez; Paul G Barghouth; Udokanma Ofoha; Devon Davidian; Frank Weckerle; Néstor J Oviedo Journal: Development Date: 2016-03-24 Impact factor: 6.868
Authors: Nancy E Thomas; Sharon N Edmiston; Audrey Alexander; Pamela A Groben; Eloise Parrish; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Lynn From; Klaus J Busam; Honglin Hao; Irene Orlow; Peter A Kanetsky; Li Luo; Anne S Reiner; Susan Paine; Jill S Frank; Jennifer I Bramson; Lorraine D Marrett; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Anne E Cust; David W Ollila; Colin B Begg; Marianne Berwick; Kathleen Conway Journal: JAMA Oncol Date: 2015-06 Impact factor: 31.777
Authors: Anne Kricker; Bruce K Armstrong; Chris Goumas; Nancy E Thomas; Lynn From; Klaus Busam; Peter A Kanetsky; Richard P Gallagher; Loraine D Marrett; Pamela A Groben; Stephen B Gruber; Hoda Anton-Culver; Stefano Rosso; Terence Dwyer; Marianne Berwick Journal: JAMA Dermatol Date: 2013-08 Impact factor: 10.282
Authors: Renee P Wood; Jane S Heyworth; Nina S McCarthy; Audrey Mauguen; Marianne Berwick; Nancy E Thomas; Michael J Millward; Hoda Anton-Culver; Anne E Cust; Terence Dwyer; Richard P Gallagher; Stephen B Gruber; Peter A Kanetsky; Irene Orlow; Stefano Rosso; Eric K Moses; Colin B Begg; Sarah V Ward Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-08-20 Impact factor: 4.254